Fatty Acid Synthase

Denifanstat (FASN-IN-2) is a FASN inhibitor with selective and oral activity. Denifanstat has been used in studies of steatohepatitis. Cost effective and quality assured.

PF429242 dihydrochloride can reversibly inhibit S1P (IC50 of 175 nM).

trans-C75 ((±)-C75) is an enantiomer of C75. C75 is an inhibitor of fatty-acid synthase (FASN).

FASN-IN-3 is an inhibitor of fatty acid synthase (FASN).

CTL-12, a fatty acid synthase (FASN) inhibitor (IC50: 2.5 μM), induces apoptosis and disrupts the cell cycle at the Sub-G1/S phase.

Fasnall HCl is a selective FASN inhibitor that acts through its co-factor binding sites.

IPI-9119 is an orally active, selective and irreversible FASN inhibitor (IC50 = 0.3 nM).

FASN-IN-4 tosylate: Fatty acid synthase inhibitor, IC50 10 nM; blocks SARS-CoV-2, EC50 18.6 nM.

Betulinditosylate is a derivative of Betulin, which functions as an SREBP inhibitor.

FASN/SCD-IN-1 is a Silybin derivative and an orally active inhibitor of fatty acid synthase (FASN) and stearoyl-CoA desaturase (SCD). In vitro, FASN/SCD-IN-1 demonstrates the ability to inhibit lipid deposition, reduce the transcription levels of FASN and SCD, and exhibits antioxidant, anti-inflammatory, and antifibrotic activities. It shows significant hepatoprotective effects in rat models of acute liver injury and improves pathological features such as steatosis, inflammation, and fibrosis in a mouse model of myeloproliferative-associated steatohepatitis (MASH). FASN/SCD-IN-1 can be used for MASH research.

CTL-06, a Fatty Acid Synthase (FASN) inhibitor with an IC50 of 3 μM, induces apoptosis, while CTL-12 impedes cell cycle progression in the Sub-G1/S phase and

MTB-9655 inhibits ACSS2 with 3.8 nM IC50, useful in research of viral, metabolic, neuropsychiatric diseases, inflammation, and cancer.

FASN Protein, Human, Recombinant (His) is expressed in E.

Anti-FASN Antibody (6U56) is an antibody targeting FASN. Anti-FASN Antibody (6U56) can be used in ELISA, IF, FCM.

GSK2194069: Fatty acid synthase inhibitor, β-keto reductase-specific, IC50 7.7 nM, hampers cancer cell proliferation.

FASN Protein, Mouse, Recombinant (His) is expressed in E.

FT113 is a novel potent inhibitor of fatty acid synthase (fasn, IC50 : 213 nM),and exhibits anti-cancer activity

Fas C-Terminal Tripeptide Acetate shows inhibitory activity of Fas/FAP-1 binding.

Ac-CoA Synthase Inhibitor1 (ACSS2 inhibitor) is the most potent and specific inhibitor of acetate-dependent acetyl-CoA synthetase 2 (ACSS2).

PF-429242 inhibits SREBP site 1 protease selectively (IC50: 0.175 μM); reduces cholesterol synthesis in CHO cells (IC50: 0.53 μM).

TVB-3664 is an orally active, selective, highly bioavailable fatty acid synthase inhibitor (FASN).Cost-effective and quality-assured.

Fatostatin inhibits SREBP-1/2 by binding to SCAP, blocking their ER-Golgi transport.

HS-80, a Fasnall enantiomer, selectively inhibits FASN, blocking lipid synthesis (IC50: 7.13 μM).

FASN-IN-5 is a FASN inhibitor, useful for studying cancer and metabolic diseases.

FAS-IN-1 is a potent inhibitor of Fatty acid synthase (FAS) wtih IC50 of 10 nM.

HS-79, a Fasnall enantiomer, selectively inhibits FASN with an IC50 of 1.57 μM, blocking tritiated acetate lipid incorporation.

C75 is an inhibitor synthetic fatty-acid synthase (FASN) and inhibits prostate cancer cells PC3 (IC50: 35 μM).

Malic enzyme inhibitor ME1 (ME1) is a specific inhibitor of Malic enzyme (IC50 = 0.15 μM). Malic enzyme inhibitor ME1 reduces cell viability/metabolic activity.

SREBP/SCAP-IN-2 (compound 13) acts as a selective inhibitor of SREBP/SCAP [1].

1,3-Dipalmitoyl-2-docosahexaenoyl glycerol, a triacylglycerol, features palmitic acid at the sn-1 and sn-3 positions and docosahexaenoic acid at the sn-2 position. Its dietary administration (30 g/kg) has been shown to decrease hepatic triglyceride and cholesterol levels in mice.

SREBP/SCAP-IN-1 (compound 10b) serves as a selective inhibitor of SREBP/SCAP [1].

FASN-in-1 is an effective, specific inhibitor of fatty acid synthase (FASN), a compound specifically designed to target and inhibit the activity of the enzyme

PFM046 is an antagonist of the liver X receptor (LXR), effectively inhibiting the activation of LXRα and LXRβ, with IC50 values of 2.04 μM and 1.58 μM respectively. It reduces the expression of SCD1 and FASN while increasing ABCA1 expression, and demonstrates antitumor activity in mouse models.

ONL-1204 is a small molecule, CD95 antigen inhibitor (Fas inhibitor) being developed by ONL Therapeutics for the treatment of retinal detachment.